Bellinato Francesco, Gisondi Paolo, Fassio Angelo, Girolomoni Giampiero
Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Section of Rheumatology, University of Verona, Verona, Italy.
Dermatol Ther (Heidelb). 2023 May;13(5):1149-1156. doi: 10.1007/s13555-023-00917-z. Epub 2023 Mar 29.
Central sensitization (CS) is a condition characterized by a disproportionate response to pain stimuli, and is associated with chronic pain conditions such as fibromyalgia, but also with inflammatory arthropathies such as rheumatoid arthritis and psoriatic arthritis (PsA). CS has never been investigated in patients with psoriasis. The aim of this study is to investigate CS in patients with chronic plaque psoriasis.
This research involved a cross-sectional observational study of adult patients with moderate-to-severe psoriasis consecutively attending the outpatient clinic of the University Hospital of Verona. Demography, measures of disease severity or activity [i.e., Psoriasis Area and Severity Index (PASI), Disease Activity in Psoriatic Arthritis (DAPSA)], diagnosis of PsA, hypertension, and diabetes were collected. Central Sensitization Inventory (CSI), Dermatology Life Quality Index (DLQI), General Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) were administered.
A total of 194 patients, including 115 (59%) men, with mean age of 54 ± 13 years, mean PASI of 12.7 ± 6.7, and mean DAPSA of 14.4 ± 3.8 were included. In total, 134 patients (79%) had only psoriasis while 60 (31%) had psoriasis and PsA; 19 (10%) patients had CSI score ≥ 40, which is the threshold for diagnosing CS. The proportion of CS ≥ 40 was higher in patients with PsA compared with psoriasis (17% versus 7%, p = 0.031). The mean CSI score in patients with PsA was higher compared with those with only psoriasis (27.5 ± 13.5 versus 20.7 ± 13.7, p = 0.002). An association between CSI and DLQI [β = 1.25 (95% CI 0.85-1.66)], PASI [β = 1.22 (95% CI 0.74-1.65)], GAD-7 [β = 2.07 (95% CI 1.69-2.45)] and PHQ-9 [β = 2.16 (95% CI 1.76-2.54)] was found independently from age, gender, diabetes, and PsA.
Central sensitization may be associated with psoriasis, particularly in those with high PASI, concomitant PsA, anxiety, depression, and severe quality of life impairment.
中枢敏化(CS)是一种对疼痛刺激反应过度的状态,与纤维肌痛等慢性疼痛疾病相关,也与类风湿关节炎和银屑病关节炎(PsA)等炎症性关节病有关。CS从未在银屑病患者中进行过研究。本研究的目的是调查慢性斑块状银屑病患者的中枢敏化情况。
本研究为横断面观察性研究,连续纳入维罗纳大学医院门诊的中重度银屑病成年患者。收集人口统计学资料、疾病严重程度或活动度指标[即银屑病面积和严重程度指数(PASI)、银屑病关节炎疾病活动度(DAPSA)]、PsA诊断、高血压和糖尿病情况。采用中枢敏化量表(CSI)、皮肤病生活质量指数(DLQI)、广泛性焦虑障碍量表-7(GAD-7)和患者健康问卷-9(PHQ-9)进行评估。
共纳入194例患者,其中男性115例(59%),平均年龄54±13岁,平均PASI为12.7±6.7,平均DAPSA为14.4±3.8。总共134例患者(79%)仅有银屑病,60例(31%)既有银屑病又有PsA;19例(10%)患者CSI评分≥40,这是诊断CS的阈值。与仅有银屑病的患者相比,PsA患者中CS≥40的比例更高(17%对7%,p = 0.031)。PsA患者的平均CSI评分高于仅有银屑病的患者(27.5±13.5对20.7±13.7,p = 0.002)。独立于年龄、性别、糖尿病和PsA发现,CSI与DLQI[β = 1.25(95%CI 0.85 - 1.66)]、PASI[β = 1.22(95%CI 0.74 - 1.65)]、GAD-7[β = 2.07(95%CI 1.69 - 2.45)]和PHQ-9[β = 2.16(95%CI 1.76 - 2.54)]之间存在关联。
中枢敏化可能与银屑病相关,尤其是在PASI高、合并PsA、有焦虑、抑郁以及生活质量严重受损的患者中。